Enable Biosciences Inc.
Medtech · Private
Dried blood spot test for Type 1 diabetes autoantibodies using patented Antibody Detection by Agglutination-PCR (ADAP) technology
enablebiosciences.com →- Grants
- $9.5M
- 15 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 3 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Development of an ultrasensitive, high-throughput autoantibody discovery platform using agglutination-PCR | $269,772 | |
| Federal grant | Department of Health and Human Services · Phase I · Antibody-Detection-by-Agglutination-PCR (ADAP): An Ultra-Sensitive, High-Throughput, Multiplexable Tool for T1D Diagnosis and Monitoring | $224,423 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II: Development of an ultrasensitive, high-throughput autoantibody discovery platform using agglutination-PCR | $899,627 | |
| Federal grant | Department of Health and Human Services · Phase II · An Ultrasensitive, High-Throughput, and Low-Cost Autoimmunity Panel for the Early Diagnosis and Improved Treatment of Type 1 Diabetes | $749,838 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Multiplex food allergy diagnostic based on IgE immunologic markers | $223,806 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Multiplex food allergy diagnostic based on IgE immunologic markers | $223,806 | |
| Federal grant | Department of Health and Human Services · Phase I · Early and accurate differential diagnosis of Lyme and other tick-borne diseases by agglutination-PCR | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · An Ultrasensitive, High-Throughput, and Low-Cost Autoimmunity Panel for the Early Diagnosis and Improved Treatment of Type 1 Diabetes | $749,838 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk | $746,584 | |
| Federal grant | Department of Health and Human Services · Phase II · Multiplex food allergy diagnostic based on IgE immunologic markers | $845,777 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of An Automated High-Throughput Dried Blood Spot Assay to Facilitate Large Scale Screening for Type 1 Diabetes Risk | $741,180 | |
| Federal grant | Department of Health and Human Services · Phase II · Multiplex food allergy diagnostic based on IgE immunologic markers | $644,600 | |
| Federal grant | Department of Health and Human Services · Phase II · Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance | $990,010 | |
| Federal grant | Department of Health and Human Services · Phase II · Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance | $968,473 | |
| Federal grant | Department of Health and Human Services · Phase II · Advancing an accessible, high-throughput and multiplex islet autoantibody test with self-collected capillary dried blood spots for regulatory clearance | $960,753 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1838 | NAMI DIAGNOSTICS LLC | — | — |
| 1839 | ENDOPROTECH, INC. | — | — |
| 1840 | SUBTLE MEDICAL, INC. | — | — |
| 1841 | Enable Biosciences Inc. | — | — |
| 1842 | Irenix Medical, Inc. | — | — |
| 1843 | CORAMIR BIOMEDICAL, INC. | — | — |
| 1844 | BMSEED, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Multiplex Competition Assay For Profiling Binding Epitopes Of Affinity Agents For Clinical Diagnostics Usegranted
- Reagents And Methods For Blocking Non-specific Interactions With Nucleic Acidsgranted
- Reagents And Methods For Blocking Non-specific Interactions With Nucleic Acidsgranted
- Multiplex Competition Assay For Profiling Binding Epitopes Of Affinity Agents For Clinical Diagnostics Useapplication
- Multiplex Competition Assay For Profiling Binding Epitopes Of Affinity Agents For Clinical Diagnostics Useapplication
- Reagents And Methods For Blocking Non-specific Interactions With Nucleic Acidsapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.